192 related articles for article (PubMed ID: 224462)
1. Morphine-naloxone interactions: a role for nonspecific morphine excitatory effects in withdrawal.
Stevens DR; Klemm WR
Science; 1979 Sep; 205(4413):1379-8. PubMed ID: 224462
[TBL] [Abstract][Full Text] [Related]
2. Nonspecific excitatory effects of morphine: reverse-order precipitated withdrawal and dose-dose interactions.
Stevens DR; Klemm WR
Psychopharmacology (Berl); 1981; 75(2):210-1. PubMed ID: 6275445
[TBL] [Abstract][Full Text] [Related]
3. Is withdrawal hyperalgesia in morphine-dependent mice a direct effect of a low concentration of the residual drug?
Rubovitch V; Pick CG; Sarne Y
Addict Biol; 2009 Sep; 14(4):438-46. PubMed ID: 19489750
[TBL] [Abstract][Full Text] [Related]
4. Injections of an opioid antagonist into the locus coeruleus and periaqueductal gray but not the amygdala precipitates morphine withdrawal in the 7-day-old rat.
Jones KL; Barr GA
Synapse; 2001 Feb; 39(2):139-51. PubMed ID: 11180501
[TBL] [Abstract][Full Text] [Related]
5. Absence of quasi-morphine withdrawal syndrome in adenosine A2A receptor knockout mice.
Bilbao A; Cippitelli A; Martín AB; Granado N; Ortiz O; Bezard E; Chen JF; Navarro M; Rodríguez de Fonseca F; Moratalla R
Psychopharmacology (Berl); 2006 Apr; 185(2):160-8. PubMed ID: 16470403
[TBL] [Abstract][Full Text] [Related]
6. Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment.
Crain SM; Shen KF
Proc Natl Acad Sci U S A; 1995 Nov; 92(23):10540-4. PubMed ID: 7479836
[TBL] [Abstract][Full Text] [Related]
7. Spinal interactions between opioid and noradrenergic agonists in mice: multiplicativity involves delta and alpha-2 receptors.
Roerig SC; Lei S; Kitto K; Hylden JK; Wilcox GL
J Pharmacol Exp Ther; 1992 Jul; 262(1):365-74. PubMed ID: 1378095
[TBL] [Abstract][Full Text] [Related]
8. Acute opioid physical dependence in postaddict humans: naloxone dose effects after brief morphine exposure.
Heishman SJ; Stitzer ML; Bigelow GE; Liebson IA
J Pharmacol Exp Ther; 1989 Jan; 248(1):127-34. PubMed ID: 2913267
[TBL] [Abstract][Full Text] [Related]
9. Effect of agonist-antagonist interaction on the development of tolerance and dependence.
Cochin J; Mushlin BE
Ann N Y Acad Sci; 1976; 281():244-51. PubMed ID: 190935
[No Abstract] [Full Text] [Related]
10. RP 67580, a selective antagonist of neurokinin-1 receptors, modifies some of the naloxone-precipitated morphine withdrawal signs in rats.
Maldonado R; Girdlestone D; Roques BP
Neurosci Lett; 1993 Jun; 156(1-2):135-40. PubMed ID: 7692360
[TBL] [Abstract][Full Text] [Related]
11. Circling behavior after narcotic drugs and during naloxone-precipitated abstinence in rats with unilateral nigral lesions.
Iwamoto ET; Loh HH; Way EL
J Pharmacol Exp Ther; 1976 Jun; 197(3):503-16. PubMed ID: 945346
[TBL] [Abstract][Full Text] [Related]
12. Increased elevated plus maze open-arm time in mice during naloxone-precipitated morphine withdrawal.
Hodgson SR; Hofford RS; Norris CJ; Eitan S
Behav Pharmacol; 2008 Dec; 19(8):805-11. PubMed ID: 19020415
[TBL] [Abstract][Full Text] [Related]
13. Naloxone rapidly evokes endogenous kappa opioid receptor-mediated hyperalgesia in naïve mice pretreated briefly with GM1 ganglioside or in chronic morphine-dependent mice.
Crain SM; Shen KF
Brain Res; 2007 Sep; 1167():31-41. PubMed ID: 17692296
[TBL] [Abstract][Full Text] [Related]
14. Naloxone precipitates nicotine abstinence syndrome and attenuates nicotine-induced antinociception in mice.
Biała G; Budzyńska B; Kruk M
Pharmacol Rep; 2005; 57(6):755-60. PubMed ID: 16382193
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological evidence for the involvement of the opioid system in the antidepressant-like effect of simvastatin in mice: Without tolerance and withdrawal syndrome.
Dolatshahi M; Davoudi S; Paridar Y; Naserzadeh R; Ghorbanzadeh B
Neurosci Lett; 2020 Jan; 714():134578. PubMed ID: 31669314
[TBL] [Abstract][Full Text] [Related]
16. Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice.
Yamaguchi T; Hagiwara Y; Tanaka H; Sugiura T; Waku K; Shoyama Y; Watanabe S; Yamamoto T
Brain Res; 2001 Aug; 909(1-2):121-6. PubMed ID: 11478928
[TBL] [Abstract][Full Text] [Related]
17. Plasma malondialdehyde levels and opiate withdrawal signs observed in rats treated with morphine plus naloxone: effects of alpha-lipoic acid administration.
Pinelli A; Cighetti G; Trivulzio S
Fundam Clin Pharmacol; 2008 Aug; 22(4):439-45. PubMed ID: 18705754
[TBL] [Abstract][Full Text] [Related]
18. Morphine analgesia and acute physical dependence: rapid onset of two opposing, dose-related processes.
Kim DH; Fields HL; Barbaro NM
Brain Res; 1990 May; 516(1):37-40. PubMed ID: 2163724
[TBL] [Abstract][Full Text] [Related]
19. Nuclear factor-kappa-B inhibitor modulates the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome.
Rehni AK; Bhateja P; Singh TG; Singh N
Behav Pharmacol; 2008 May; 19(3):265-9. PubMed ID: 18469544
[TBL] [Abstract][Full Text] [Related]
20. Acute opioid physical dependence in humans: effect of varying the morphine-naloxone interval. I.
Heishman SJ; Stitzer ML; Bigelow GE; Liebson IA
J Pharmacol Exp Ther; 1989 Aug; 250(2):485-91. PubMed ID: 2760839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
